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ABSTRACT 
Duchenne muscular dystrophy (DMD) is a lethal muscle-wasting disease currently 
without cure. We investigated the use of the PiggyBac transposon for full-length 
dystrophin expression in murine mesoangioblast (MABs) progenitor cells. DMD 
murine MABs were transfected with transposable expression vectors for full-length 
dystrophin and transplanted intra-muscularly or intra-arterially into mdx/SCID mice. 
Intra-arterial delivery indicated that the mesoangioblasts could migrate to 
regenerating muscles to mediate dystrophin expression. Intra-muscular transplantation 
yielded dystrophin expression in 11-44% of myofibers in murine muscles, which 
remained stable for the assessed period of five months. The satellite cells isolated 
from transplanted muscles comprised a fraction of MAB-derived cells, indicating that 
the transfected MABs may colonize the satellite stem cell niche. Transposon 
integration site mapping by whole-genome sequencing indicated that 70% of the 
integrations were intergenic, while none was observed in an exon. Muscle resistance 
assessment by atomic force microscopy indicated that 80% of fibers showed elasticity 
properties restored to those of wild type muscles. As measured in vivo, transplanted 
muscles became more resistant to fatigue. This study thus provides a proof-of-
principle that PiggyBac transposon vectors may mediate full-length dystrophin 
expression as well as functional amelioration of the dystrophic muscles within a 
potential autologous cell-based therapeutic approach of DMD.  
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INTRODUCTION 
Duchenne Muscular dystrophy (DMD) is a lethal X-linked muscular dystrophy 
affecting 1 in 5000 boys.1,2 DMD results from various types of mutations in the 
dystrophin gene that lead to progressive muscle wasting, cardiomyopathy and 
respiratory failure.3 Despite several research approaches to find a potential cure for 
the disease, success remains modest. The current palliative care for patients includes 
the use of anti-inflammatory drugs and corticosteroids, which have been shown to 
prolong life expectancy to about 30 years of age.4 
Dystrophin provides a physical link between the cytoskeleton of the muscle fiber and 
the extracellular matrix, and it is required for the assembly and maintenance of the 
dystroglycan complex.5 The absence of this protein causes muscle fiber degeneration, 
inflammation and necrosis, and progressive replacement of muscle with scar and fat 
tissue. Among the potential treatment strategies that were assessed, exon skipping is 
one of the most advanced today.5,6 Exon-skipping techniques are promising for the 
treatment of many types of mutations affecting dystrophin, allowing the skipping of 
single or multiple exons. This method is expected to convert the severe dystrophic 
phenotype of DMD patients into milder Becker muscular dystrophy-like phenotypes, 
however it may not be suitable to treat all DMD-causing mutations.7,8 
Cell transplantation-based approaches were also attempted. Skeletal muscle fibers are 
multi-nucleated, hence restoring dystrophin expression in one nucleus may provide 
functional restoration of the entire muscle fiber.9 However, muscles are among the 
most abundant tissues of the body, and systemic correction might require the 
engraftment of billions of cells. Gene transfer based approaches are limited by the 
large size of the dystrophin coding sequence, by transgene silencing issues, as well as 
by the difficulty of mediating systemic and sustained dystrophin expression10. A 
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11.1kb open reading frame is required to encode the 427kDa full-length protein, 
which is difficult to integrate into lenti- and retro-viral gene therapy vectors. Thus, in 
vivo gene therapy has been attempted using helper-dependent adenoviral vectors that 
may carry the full-length dystrophin coding sequence, but show limitations with 
respect to mediating therapeutic dystrophin levels in the entire musculature. Adeno-
associated viral (AAV) vectors are another attractive option for efficient systemic 
delivery in the muscles, however their use is hampered by their restricted packaging 
capacity.11 Human artificial chromosome vectors provide another approach towards 
the expression of the entire dystrophin coding sequence, but face the difficulty of 
inefficient production and delivery.12,13 
Gene editing approaches using CRISPR-Cas9 system have also being explored in 
mouse models, however they cannot be used efficiently to correct large deletions, 
which form a majority of the mutations in patients, and efficacy on large populations 
of cultured cells remains limiting.14–17 Other pursued alternative approaches consist of 
the use of truncated versions of the dystrophin sequence encoding micro or mini-
dystrophin proteins, and the up-regulation of utrophin, the homologue of 
dystrophin.18,19,20,21,22  
Transposable vectors stably integrate their cargo into permissive regions of the target 
cell genome, hence enabling long-term expression of the therapeutic genes.23,24 For 
instance, the Sleeping Beauty transposon system has been used for the expression of 
micro-dystrophin, a shortened version of dystrophin, and dysferlin in muscle 
dystrophy murine models, and it was optimized for use in a clinical setting.25,26,27 
PiggyBac (PB) transposons, originally identified in the cabbage looper moth 
Trichoplusia ni, are also able to efficiently transpose in mammalian cells with a large 
cargo DNA capacity, and PB-derived vectors were shown to mediate stable 
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expression of full length dystrophin.28 They combine the easier production of non-
viral vectors with efficient transposition and sustained expression in a broad variety of 
cell types.29 Although transposons share the limitations of other non-viral vectors 
regarding a less efficient intracellular delivery relative to viral vectors, they are 
among the most promising non-viral vectors for gene therapy applications because of 
their versatility. PB transposon vectors typically consist of transposon donor plasmids 
containing a therapeutic gene flanked by the PB transposon inverted terminal repeat 
(ITR) sequences. They are provided together with a distinct source of the PB 
transposase, which binds the ITR and mobilizes the transposable vector to mediate 
genomic integration by a cut-and-paste mechanism.30 
Here, we aimed at investigating an autologous cell therapy approach based on full-
length dystrophin expression in mesoangioblasts (MABs), as PB transposon vectors 
were previously found to yield stable transgene expression in these cells.28,31 MABs 
are progenitor cells associated with blood vessels which are able to differentiate into 
several mesenchymal tissues, including skeletal muscle.32 These cells are an attractive 
option for cell therapy, as they are relatively easy to isolate and culture in vitro, they 
retain their differentiation properties after culture, they efficiently differentiate into 
muscle cells in the context of damaged muscle tissues, and they are able to cross 
blood vessel walls, hence making systemic distribution and migration to regenerating 
muscle possible.33,34 MABs were shown to infiltrate dystrophic muscle from the 
circulation, engraft into host fibers with high efficiency, and bring along therapeutic 
genes and proteins. MABs provide such effect either by direct fusion with the muscle 
fibers or by entering the muscle satellite cell niche.12,34 These are promising properties 
for the systemic and sustained treatment of muscular dystrophies such as DMD. 
Given their therapeutic potential to improve muscle structure and function in a large 
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animal model, allogeneic MAB transplantation was used in a clinical trial, 
demonstrating the safety of this approach, however there was no improvement in 
phenotype after this transplantation.34,35 
In this study, we wished to establish the use of the native PiggyBac transposon 
vectors for the expression of full-length dystrophin in MABs, and to assess the 
therapeutic potential of these MABs following transplantation in the mouse model of 
DMD. We show that PB-mediated dystrophin coding sequence delivery in mdx mice 
MABs, followed by cell transplantation into dystrophic mdx/SCID mice, led to 
dystrophin expression in mouse muscles and to morphological and functional 
amelioration of the dystrophic phenotype in mdx/SCID mice. 
 
RESULTS 
Characterization of mdx MABs corrected using transposable vectors 
The strategy assessed in the present study involved the isolation of MABs from mdx 
mice and their transfection using the non-viral PiggyBac transposon vectors 
expressing dystrophin and/or a reporter gene. This was followed by transplantation of 
the selected myogenic progenitors into dystrophic mouse muscles, and by the 
characterization of the transplanted cells and muscles for morphological and 
functional amelioration of the dystrophic phenotype, as summarized in Figure 1. 
PiggyBac transposon donor plasmids were constructed to express the full-length 
human dystrophin coding sequence, under control of a truncated muscle creatine 
kinase (MCK) promoter. A GFP or nlacZ reporter gene under control of a constitutive 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter was expressed on a 
separate transposon donor plasmid. The PB transposase was expressed from another 
plasmid under control of the simian cytomegalovirus IE94 promoter, as performed in 
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a previous study showing that transposase expression mediated sustained reporter 
gene expression from transposable vectors in murine muscles.31  
To investigate whether the transposable vector system could restore dystrophin 
expression in the DMD mouse model, we first isolated MABs from mdx mice (mdx 
MABs). The dystrophin and GFP or lacZ expressing transposon donor plasmids were 
introduced in mdx MABs together with the transposase encoding plasmid by 
electroporation. Cells having integrated dystrophin and/or reporter transgenes into 
their genome were selected by puromycin antibiotic resistance. These cells were 
called mdx (DYS GFP/nlacZ PB) MABs according to the integrated transgenes 
(Figure 2A). These polyclonal cell populations were characterized for the 
maintenance of MAB cell markers and for their differentiation and migration potential 
in vitro (Figure 2B-E, Supplementary figure S1). The mdx (DYS PB) MABs also 
retained the different regions of the human dystrophin coding sequence, as verified by 
endpoint PCR (Figure 2F). Differentiation of mdx MABs in vitro when co-cultured 
with mouse C2C12 myoblasts was assessed by the staining the differentiated 
myotubes with anti-myosin heavy chain antibody and by observing GFP positive 
myotubes (Figure 2B). The genetically modified mdx MABs retained their 
morphology, migration and differentiation properties, and their cell surface markers 
were comparable to those of the parent mdx MABs, as assessed by flow cytometry or 
by transcript level analysis (Figure 2C and 2D). These properties did not vary along 
culture passages (data not shown). 
Cell survival following transfection and the transposition efficiency were assessed, 
indicating that 0.226% of the transfected cell population had survived transfection and 
had integrated at least one transgene copy in presence of the transposase, whereas the 
spontaneous plasmid integration frequency observed in the absence of the transposase 
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was much lower (0.026%, see Supplementary figure S2A, B, C). The overall pattern 
of transposable vector mediated transgene integration in the MAB genome was 
assessed by sequencing the genomes of a polyclonal population of mdx (DYS PB) 
MABs. Transposon integration sites were identified from the sequencing reads 
spanning both the genome and vector. This approach led to the recovery of 44 distinct 
integration sites spread over 17 chromosomes of the mouse genome, without a 
detectable preference for specific chromosomes or genomic loci, as illustrated in 
Figure 3A. 70% of the integration sites were in intergenic regions, and all integration 
sites within genes were found to be intronic, none was located in an exon (Figure 
3B). To investigate if integrations occurred with a preference for upstream regulatory 
regions such as promoters or enhancers, the occurrence of integration events was 
plotted relative to the nearest gene sequence and orientation. Most integration sites 
were scattered beyond 1 kb upstream or downstream of coding sequences, with just 
11% of the integrations within 1000bp of a transcription initiation site (Figure 3B, 
C). The total number of integration sites per genome was also assessed using qPCR, 
using both a standard calibration method and comparison to a reference cellular gene 
for normalization, in addition to whole genome sequencing. These methods revealed 
between two to six integration events per MAB haploid genome (Supplementary 
Figure S2D). Overall, these results were consistent with previous findings that few 
transposon integration events can lead to sustained transgene expression.31  
 
Dystrophin expression from mdx (DYS GFP/nlacZ PB) MABs muscle 
transplantation 
To assess whether the corrected MABs would engraft and differentiate into muscle 
fibers in vivo, mdx (DYS GFP PB) MABs were transplanted in dystrophic 
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immunodeficient (mdx/SCID) mice, to avoid immune rejection due to the expression 
of the human dystrophin and reporter genes. Approximately 500,000 cells were 
transplanted intramuscularly in the tibialis anterior (TA) muscle of mdx/SCID mice, 
either as a single transplant or as three successive transplants at an interval of three 
weeks, after a pretreatment of the muscles with cardiotoxin 24h prior to the first MAB 
intramuscular injection, to better mimic the more severe condition of the muscles of 
human dystrophic patients. Single transplanted mice were assessed at 45 days (short 
term) or 120 days (long term) after transplant, and three times transplanted mice were 
assessed 45 days after the last transplant. All the transplanted muscles showed 
extensive GFP positive areas when observed under a fluorescence microscope 
(Supplementary Figure S3). Muscle cross sections showed the presence of extensive 
areas of dystrophin-positive fibers, with correct sarcolemmal membrane localization, 
which indicated extensive engraftment of donor mesoangioblasts and sustained 
dystrophin expression thereafter (Figure 4A, Supplementary Figures S4 top panel 
and S5). Quantification of dystrophin positive fibers in serial cross sections showed 
between 200 to 800 dystrophin positive fibers in single transplanted muscles (short 
and long term), and 300 to 2500 positive fibers in the muscles transplanted 3 times 
(Figure 4B). This constituted between 3 to 19% of dystrophin-positive fibers in the 
cross section in single transplanted muscles (short and long term), and 11 to 44% of 
the fibers in muscles transplanted 3 times. These numbers were clearly higher than 
those of the revertant fibers seen in non-transplanted TA muscles, which were 6-10 
dystrophin positive fibers per muscle cross section. The number of dystrophin 
positive fibers remained at similar levels in the mid-belly of the transplanted muscles 
(5 to 8 mm from the distal tendon) in all the transplant conditions, revealing that there 
may be fiber length expression in some of the dystrophin positive fibers (Figure 4B). 
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Interestingly, the number of dystrophin positive fibers observed after a single 
transplant remained stable even up to four months after transplantation (Figure 4D).  
Semi-quantitative analysis of dystrophin signal intensity, as assessed by 
immunofluorescence and confocal microscopy, revealed that the dystrophin signal 
intensity of areas with a high proportion of dystrophin-positive myofibers in treated 
muscles was similar to that of wild type mice muscles (Supplementary Figure S6). 
Also, immunofluorescence analysis of transplanted muscles showed reconstitution of 
the dystrophin protein complex, as evidenced with α-sarcoglycan, β-sarcoglycan, β-
dystroglycan, syntrophin, neuronal nitric oxide synthase (nNOS) (Supplementary 
Figure S7). RT-PCR analysis confirmed correct expression of the muscle isoform of 
dystrophin (Dp427m) (Supplementary Figure S8) and RT-qPCR showed that 
dystrophin transcript accumulation in the muscles was increased approximately three-
fold after three transplantations (Figure 4E). Similar observations were found by 
qPCR analysis of DNA from transplanted muscles, where DNA levels of the 
dystrophin vector were approximately three times higher in muscles transplanted 3 
times than those of single transplanted muscles at short time point (Figure 4C), 
suggesting improved engraftment upon successive transplantations. However, 
transposase DNA levels were essentially undetectable in the transplanted muscles, 
implying a low risk of in vivo transposition events post-engraftment. Assessment of 
backbone plasmid DNA levels by qPCR also indicated almost undetectable levels, 
consistent with mainly transposon-mediated cargo DNA integrations (Figure 4C). 
Moreover, western blot analysis showed that transplanted muscles expressed 20-40% 
of dystrophin levels as compared to non-dystrophic B6/SCID mice, as estimated from 
densitometry analysis of Western blots, which correlates well with the proportion of 
dystrophin-expressing myofibers (Figure 4F). 
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Because the diffuse GFP signal was not readily detected in cross-sections following 
MAB muscle transplantation, we next used the nuclear localized nLacZ reporter 
coding sequence. Upon intra-arterial transplantation of mdx (DYS nlacZ PB) MABs 
into the femoral artery of mdx/SCID mice, small clusters of dystrophin positive fibers 
were observed in the gastrocnemius muscle cross sections (35-45 dystrophin positive 
fibers/cross section) four weeks after transplant (Supplementary Figure S4 lower 
panel). A few nLacZ+ nuclei were also visible in the interstitium in other area of the 
grafted muscles, but their numbers were too low to be reliably quantified. These 
numbers are in agreement with previously reported results of intra-arterial MAB 
transplantation.12 These results established that the transposon modified MABs 
retained their ability to migrate through the vasculature and engraft into regenerating 
muscles upon systemic transplantation, although the numbers of dystrophin positive 
fibers were lower than those obtained from intramuscular injection. 
Overall, it was noteworthy that dystrophin expression levels after intramuscular 
transplantation, were maintained at essentially constant levels at the longest time 
point assessed, four months after transplantation, and that the dystrophin DNA, RNA 
levels and number of dystrophin positive fibers in muscles transplanted 3 times was 
three-fold higher than those of single transplanted muscles. Overall, these data 
indicated that the genetically modified MABs were able to engraft into murine 
muscles and to mediate dystrophin expression, which in turn was able to restore the 
proper localization of the other components of the dystroglycan complex. 
 
Transplanted MABs seed the satellite cell compartment 
In order to examine whether transplanted MABs are able to contribute to the muscle 
satellite cell pool, we transplanted (DYS nlacZ PB) MABs intramuscularly into 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 12
mdx/SCID mice. Two months after cell transplantation, muscle cross sections were 
stained with Pax7 (satellite cell marker), laminin and β-galactosidase antibodies. A 
fraction of the β-galactosidase positive cells were found to display some 
characteristics of satellite cells, being associated to the basal lamina of transplanted 
muscles and displaying Pax7 expression (Figure 5A).12 Hence, the transplanted mdx 
(DYS nlacZ PB) MABs may have retained the ability to colonize the satellite cell 
niche of the muscle. Muscle satellite cells were also isolated from muscles 
transplanted with mdx (DYS GFP PB) MABs by flow cytometry, showing that 
approximately 3% of the Intα7+, Sca1-, CD31-, CD45-, CD11b- cells were also GFP 
positive, and thus originated from the donor MABs, in the muscles transplanted 3 
times (Figure 5B, C, Supplementary Figure S9 and S10). This was significantly 
higher than the 0.12% of such cells in single transplanted muscles. A possible reason 
for this observation may be that the MABs of the first transplant may preferentially 
fuse with the distressed dystrophic myofibers, whereas the MABs delivered during 
the second and third transplantations may lead to the almost 25-fold increase in the 
MAB-derived population of satellite-like cells. 
The satellite-like cells derived from the transplanted MABs were sorted as based on 
GFP fluorescence from the Intα7+, Sca1-, CD31-, CD45-, CD11b- cell population, and 
they were analyzed for other markers of native satellite cells. The relative transcript 
levels of the Pax7 and integrin α-7 satellite cell marker genes were comparable in the 
GFP+ MAB-derived transplanted cells and in the native satellite cells of non-
transplanted muscles (Figure 5D). We concluded that the genetically modified MABs 
could contribute to both differentiating into muscle fibers as well as to replenishing 
the pool of muscle progenitor cells, in agreement with previous studies.12 We 
therefore hypothesized that the MAB-derived satellite-like cells might contribute 
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dystrophin positive myofibers in a time-sustained fashion, to possibly reduce the 
progression of the dystrophic disease. 
 
Morphological amelioration of dystrophic muscles after MAB transplantation 
To understand whether the restoration of dystrophin expression in the transplanted 
muscles led to a morphological amelioration of the dystrophic phenotype, fibrotic and 
scar tissue infiltration was quantified, along with the cross sectional area of individual 
fibers. The muscles of mdx/SCID mice showed the typical infiltration of muscle by 
mononuclear cells and the replacement of muscle tissue by fibrotic infiltrates and fat 
tissue (Figure 6A). Cross-sectional areas of individual fibers of the transplanted 
muscles had reduced variability relative to those of untreated muscles of mdx/SCID 
mice (Figure 6B and Supplementary Figure S11). Morphometric analyses revealed 
a marked reduction in the fibrotic and cellular infiltrates of transplanted dystrophic 
muscles, indicating that treated muscle underwent fewer degeneration-regeneration 
cycles. The overall percentage of muscle area replaced by fibrotic or scar tissue was 
significantly reduced in the transplanted muscle cross sections, from 8 to 14% in the 
non-treated dystrophic muscle to 4 to 10% in the transplanted muscles (Figure 6C). 
 
Functional amelioration of the dystrophic phenotype after MAB transplantation 
To investigate whether engraftment and restoration of dystrophin expression was 
accompanied by improvement in muscle function, we evaluated the functional 
properties of transplanted muscles. Previous studies indicated that atomic force 
microscopy (AFM) nano-indentation assays are capable of detecting changes in the 
resistance to elastic deformation of individual myofibers within muscle explants, as 
evoked by the presence or absence of dystrophin at the sarcolemmal membrane.36,37 
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Six weeks after a single or three consecutive intramuscular transplantations, myofiber 
elasticity was probed on longitudinal sections of TA muscles on randomly chosen 
myofibers at over 100 locations.  
The myofiber resistance to elastic deformation was quantified through Young’s 
modulus value (E), which for dystrophin-expressing B6/SCID control muscles was 
18.1±9.9 kPa (Figure 7A). Significantly lower (p<0.001) Young’s modulus of 
8.5±5.3 kPa was obtained for mdx /SCID muscles, indicating lower resistance to 
applied pressure, as expected.36,37 The Young’s modulus, i.e. the resistance to 
deformation, of single transplanted muscles was not significantly higher than those of 
mdx/SCID muscles (9.6 ± 4.8 kPa). However, after three MAB transplantations, a 
bimodal distribution of the Young’s modulus values was observed, with a 
subpopulation of myofibers having elasticity similar to those of control non-
dystrophic muscles (17.2±4.2 kPa, Figure 7A). It was possible to infer from this 
distribution that 80% of the measured fibers had resistance properties similar to 
healthy muscles, whereas 20% retained the properties of dystrophic myofibers. 
Myofibers with a dystrophic or non-dystrophic phenotype were detected as clusters, 
as was noted for dystrophin expression and for the restoration of dystrophin-
associated protein clusters (Supplementary Figure S4, S5 and S7B). Interestingly, 
the proportion of myofibers displaying normal elasticity properties was higher than 
those where dystrophin expression could be detected (80% vs. 45%). This is in 
agreement with the previous observations that low dystrophin expression levels, 
which are not easily detected by immunofluorescence, may suffice to restore full 
myofiber resistance.38 Thus, immunofluorescence assays likely underestimated the 
proportion of fibers having elevated dystrophin expression following transplantation. 
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To further investigate functional restoration in muscles transplanted 3 times, we 
performed isometric force measurement on the TA muscles. Tetanic or phasic force 
parameters were not significantly altered in the transplanted muscles (not shown). 
However, MAB transplantation caused a significant restoration of the muscle 
resistance to fatigue upon repeated tetanic contractions above the untreated mdx/SCID 
muscles (Figure 7B-C). Contraction-induced fatigue, a major cause of weakness of 
dystrophic muscle, was prevented by more than 60% in muscles injected 3 times with 
MABs. Overall, we conclude that the dystroglycan complex and hence the 
sarcolemmal integrity in the dystrophin-restored regions may be restored in mdx 
myofibers, conferring the transplanted muscles with physical properties similar to 
those of wild type muscles and providing an improved resistance to fatigue.  
 
DISCUSSION 
Stem cell technologies have the potential to revolutionize medical care as well as 
provide improved prospects for addressing a host of untreatable muscular 
dystrophies.39 The therapeutic potential of muscle stem cells so far has been limited 
because of their low abundance in adult muscle, and by the fact that in vitro 
expansion of these cells results in reduced engraftment ability.40 Also, until now, 
persistent expression of full-length dystrophin in mouse muscles has been difficult to 
achieve.12,41 It was recently shown that stable transgene expression can be achieved 
using PiggyBac vectors and MAB transplantation in murine muscles in vivo and that 
the expression of full-length dystrophin could be mediated by such transposable 
vectors in vitro. However, whether this may provide a functional amelioration of 
dystrophic muscles in vivo had not been reported.28,31 This study shows that MABs 
modified with PiggyBac transposon vectors can yield large numbers of dystrophin 
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expressing fibers when transplanted into dystrophic immunodeficient mice, and that 
this leads to a functional improvement of the transplanted muscles, hence fulfilling 
some of the criteria required for successful cell therapy of muscular dystrophy. 
The genetic modification of MABs by PiggyBac transposon vectors has several 
advantages, especially in context of dystrophin, because of their ability to deliver very 
large DNA cargoes into the genome and to enable stable integration and long-term 
expression of full-length dystrophin.28 Also, considering the undesirable aspects of 
allogeneic transplantation, such as lifelong immune suppression and limited 
effectiveness, the use of autologous genetically corrected MABs may be a preferred 
strategy to avoid confronting these issues. An ideal therapeutic strategy would be one 
in which full-length dystrophin coding sequence would be integrated in non-coding 
regions of the MABs genome, to allow sufficient transgene expression while avoiding 
mis-regulation of endogenous cellular genes. Our observations that vector copy 
number is between two to six per MAB genome, and that 70% of the integrations are 
in non-coding regions provide significant steps towards this goal. Nevertheless, 
previous studies have reported that PB transposition events may be favored at 
transcription start sites, and also that vertebrate genomes bear genes distantly related 
to PB transposase that can nevertheless mobilize the insect PB transposon in human 
cell cultures when expressed ectopically.42,43,44 More extensive analysis will be 
required to evaluate further the PB integration profile and the risk of potential 
genotoxicity resulting from these transposable vectors. Several potential 
improvements to this strategy may be envisaged for potential clinical use, such as 
further reducing integrated vector copy number, employing other selection strategies 
than antibiotic resistance, transposon targeting into safe harbors in the genome e.g. 
with CRISPR-Cas9, and/or use of a more active transposase. Although we did not 
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observe disruption of any exons in this study, nor did we observe any tumorigenesis 
from the transposon-containing MABs (data not shown), these additional precautions 
might be needed to further reduce the potential risk of adverse effects due to 
insertional mutagenesis or mis-regulation of cellular genes. 
The levels of dystrophin protein expression achieved in transplanted muscles was 20 
to 40% of the wild type levels on a whole-muscle basis. However, positive myofibers 
of transplanted muscles yielded dystrophin expression up to levels that were 
comparable to those of wild-type muscles. This was sufficient to ameliorate the 
dystrophic phenotype, as assessed by histological studies, and to restore normal 
resistance of most mdx/SCID myofibers in AFM studies. This is consistent with 
previous studies which reported that even moderate dystrophin expression levels can 
provide improved muscle structure and function.12,14,15,17,45,38 Such level of dystrophin 
expression also yielded improved fatigue resistance properties of the treated 
mdx/SCID muscles.  
In clinical protocols, systemic delivery may be imperative for fighting the DMD 
disease, as intra-muscular delivery would require an excessive number of injections, 
including in difficult to reach muscles. MABs were previously shown to be able to 
cross blood vessel walls and to diffuse into- and engraft in- regenerating skeletal 
muscle when delivered intra-arterially.12,33,34 This study shows that transposon-
containing MABs transplanted into the femoral artery retained ability to migrate 
across the vessel walls into neighboring muscles where dystrophin-expressing muscle 
fibers could be detected. However, future studies should seek to further improve the 
efficiency of IA transplantation, and also to determine if these findings can be 
extrapolated to human MABs, which have similarities and also some differences 
relative to their murine counterparts.46  
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Taken together, our findings provide a proof-of-concept for the feasibility of 
combining MAB transplantation with genetic complementation using the PiggyBac 
transposon system for a potential treatment of Duchenne muscular dystrophy. This 
study shows that a fraction of the non-virally corrected mdx MABs may have 
colonized the satellite cell niche upon their engraftment into transplanted muscles. 
This engraftment could restore dystrophin and dystroglycan protein complex 
components, thereby mediating morphological amelioration of the dystrophic 
phenotype, restoring myofiber stiffness to normal levels and improving the muscle 
resistance to fatigue. 
As of today, exon skipping and premature stop codon read-through are among the 
most advanced innovative strategies for the treatment of DMD. However, a 
significant proportion of DMD mutations may not be corrected using these 
approaches. By contrast, autologous cell transplantation using modified MABs 
carrying the entire dystrophin cDNA may be a promising therapeutic avenue for the 
treatment of DMD patients bearing any mutation.  
 
 
MATERIALS AND METHODS  
Animal models and experimentation 
All animal experimentations were done in accordance with institutional guidelines 
and authorizations for animal research by the State of Vaud veterinary office. 
Mdx/SCID (B10ScSn.Cg-Prkdcscid Dmdmdx/J) and B6/SCID (B6.CB17-Prkdcscid/SzJ) 
were purchased from Jackson Laboratory (Jackson, Bar Harbor, ME). They were bred 
and maintained in a specific pathogen free (SPF) animal facility (University of 
Lausanne). CD1 nude mice for tumorigenesis assays were purchased from Charles 
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River, France, and housed in an SPF animal facility. Mice were given ad libitum 
access to food and water, the temperature was maintained at 21°C and humidity at 50-
60%. Mice were age, sex and background-matched with their controls for all 
morphological and functional analysis.  
Prior to intra-muscular (IM) transplantation, mice were anesthetized with isoflurane 
and injected intramuscularly with cardiotoxin (10 µM, 25 µL), so as to induce muscle 
regeneration.47 IM transplantations were done by injecting 500,000 mdx (DYS GFP 
PB/DYS nlacZ PB) MABs resuspended in 25 µL of Ca2+ and Mg2+ free PBS into the 
muscles of anesthetized mice using a 30G needle (BD Biosciences). Transplantations 
were either a single IM transplantation, or three consecutive intramuscular 
transplantations at an interval of three weeks, with each injection consisting of 
500,000 cells. The muscles from age, sex and background-matched control mice were 
injected with 25 µL Ca2+ Mg2+ free PBS. The muscles were explanted and used for 
various assays at different time points: 45 days after a single transplantation for short 
term assays (1 transplant ST), 120 days after single transplantation for long term 
assays (1 transplant LT); or following three transplants 45 days after the last 
transplant (3 transplants). 
Intra-arterial (IA) transplantations were performed by injecting 500,000 mdx (DYS 
GFP PB/DYS nlacZ PB) MABs resuspended in 100 µl Ca2+ and Mg2+ free PBS into 
the femoral artery of previously exercised mice (flat treadmill to exhaustion allowing 
the mice to run till they reach fatigue, a day before injection) so as to induce muscle 
regeneration and to mimic the more severe condition of human DMD patients. The 
mice were kept under anesthesia (isofluorane, Attane®), while the artery was isolated 
and cells were injected into the artery, as previously described.48 
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Eight to ten week old male mice were used in the study. The total number of grafted 
mice for single intramuscular transplantations was 20, whereas it was 40 mice for 
three consecutive intra-muscular transplantations, and 8 mice for intra-arterial 
transplantations.  
 
Cell culture and plasmids 
MABs were isolated from mdx mice as previously described.46 Briefly, muscles from 
7-day old mice were dissected and minced into 1 mm2 pieces. These pieces were 
transferred onto collagen type I-coated dishes (Sigma, St Louis, MO), and incubated 
with 50 µL of DMEM culture medium (Gibco, Grand Island, NY) supplemented with 
20% fetal bovine serum (FBS) (Lonza, Basel, Switzerland), 2 mM L-glutamine, 
1 mM sodium pyruvate, 1x non-essential amino acids, 100 IU/mL penicillin and 
100 mg/mL streptomycin (Gibco, Grand Island, NY). After seven days, the primary 
cell outgrowth was collected, and alkaline phosphatase positive cells (Mouse alkaline 
phosphatase antibody, R&D systems, Minneapolis, MN) were sorted by FACS (BD 
FACS Aria II, BD Biosciences, San Jose, CA). This MAB cell population was 
expanded and maintained at 37°C, 5% CO2, on collagen coated plastic dishes. MABs 
were tested for alkaline phosphatase expression using the Alkaline Phosphatase Live 
Stain (Molecular Probes, Burlington, Canada), as per the manufacturer’s instructions. 
The live stained cells were observed under a fluorescence microscope for green 
fluorescence. The MABs were found to be alkaline phosphatase positive, in 
agreement with their previously reported phenotype (data not shown). 46 
C2C12 mouse myoblasts were maintained in DMEM containing 10% FBS. In order to 
avoid differentiation, cells were not allowed to reach more than 80% confluence. The 
differentiation ability of MABs was tested by co-culture with C2C12 cells (2:1 ratio 
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of C2C12 cells to GFP tagged MABs) for seven days in differentiation medium 
(DMEM supplemented with 2% horse serum (Gibco), 2 mM L-glutamine, 100 IU/mL 
penicillin and streptomycin).46 The resulting myofibers were stained for myosin-
heavy chain MF20 (ThermoFisher, Waltham, MA) to confirm differentiation into 
myotubes. For promoting the differentiation of MABs into smooth muscle cells, 
smooth muscle induction medium (DMEM supplemented with 2% horse serum 
Gibco, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 IU/mL penicillin and 
100 µg/mL streptomycin, 5 ng/mL TGFβ1 (Peprotech, Rocky Hill, NJ).  
The PiggyBac transposase expression vector has been previously described.31 Briefly, 
the 3’ UTR 317 bp fragment from pBSSK/SB10 (kindly provided by Dr S. Ivics) was 
inserted into pCS2+U5 (Invitrogen/Life Technologies, Paisley, UK) to yield 
pCS2+U5U3. The PB transposase coding sequence (2067 bp, GenBank accession 
number: EF587698) was cloned into the pCS2+U5U3 backbone between the two 
UTRs. The PB transposon vectors used in the study were generated by introducing the 
PB 235 bp 3’ and 310 bp 5’ inverted terminal repeats (ITRs) into the pBluescript SK 
plasmid. The 11.1kb human full-length dystrophin coding sequence was kindly 
provided by J. Tremblay.49 It was cloned into the PiggyBac transposon vector 
backbone under the previously described truncated muscle creatine kinase (MCK) 
promoter.31,50 A puromycin resistance cassette was introduced into this construct 
under the control of an SV40 early promoter. Alternatively, a GFP/nlacZ reporter 
cassette was cloned in the same PiggyBac vector under control of the human GAPDH 
promoter.31 Endotoxin-free plasmid preparations (Qiagen endo-free plasmid maxi kit / 
GeneArt plasmid purification service from Thermo Fisher Scientific) of all the 
plasmids were used for transfection into mdx MABs. 
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The transposon and transposase expression vectors were introduced by transfection of 
the MABs using Neon electroporation (Invitrogen, Carlsbad, CA), as per the 
manufacturer’s instructions. One million MABs were co-transfected with 20 µg 
transposon, 4.5 µg transposase, and 2 µg reporter expression vectors at 1300V for two 
pulses. The metabolic activity and cell survival rates were assessed by Alamar blue 
staining or propidium iodide dye exclusion assays, respectively, one day after 
transfection. Two days after transfection, the cells were placed in medium containing 
2 µg/mL puromycin and the cells were further cultured for two weeks with medium 
replacement two times per week. Methlylene blue staining of the colonies formed by 
resistant cells was performed after electroporation and antibiotic selection to 
determine the transposition efficiency and background levels of random integration. 
The transfected and selected mdx MABs are henceforth called mdx (DYS GFP PB), 
(DYS nlacZ PB) or (DYS PB) MABs, where the transgene names within the 
parenthesis indicates which expression vectors were used, e.g. mdx MABs co-
transfected with the transposon donor plasmids containing dystrophin coding 
sequence (DYS) and GFP coding sequence (GFP), and with the transposase 
expression plasmid (PB), are called mdx (DYS GFP PB) MABs. 
MABs were prepared for flow cytometry analysis by washing the cells with PBS, and 
staining with antibodies for CD44, Sca1, CD45 and CD31 conjugated to 
allophycocyanin or PerCP (R&D systems) for one hour. This was followed by 
washing again with PBS to remove the excess antibody and finally the cells were 
resuspended in PBS supplemented with 2% FBS. The analysis was performed on a 
Beckman Coulter CyAn ADP (Beckman Coulter, Brea, CA). At least 10,000 events 
were acquired for each sample. 
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In vitro cell transmigration assay was performed as previously described.48 Briefly, 
mdx (DYS GFP PB) MABs were cultured on a layer of mouse endothelial cells (H5V) 
in Transwell® plate inserts (Corning, Corning, NY). The mdx (DYS GFP PB) MABs 
migrated on the other side of the filter were counted 11h after seeding (10 random 
fields at 10x magnification under a fluorescence microscope). 
 
Satellite cell isolation 
Satellite cells were isolated from TA muscles of mdx SCID mice transplanted with 
mdx (DYS GFP PB) MABs 90 days after transplantation, as described previously.51 
Briefly, muscles were minced and resuspended in 700-800 U/mL of collagenase II 
solution for 30 minutes and then washed in Ham’s F10, 10% Horse Serum, 100 IU/L 
Penicillin and 100mg/mL Streptomycin medium. A second digestion with collagenase 
II (1000U/mL) and dispase II (11U/mL) followed, after which the suspension was 
strained through 70 µm and 40 µm strainers (Falcon, Corning, NY) and collected in 
the wash medium. The cell suspension was then stained with antibodies for Integrin 
α-7 (Miltenyi Biotec, Bergisch Gladbach, Germany) recognized by an anti-mouse IgG 
conjugated with PE/Cy7 (R&D systems), Sca-1 conjugated with BV421(R&D 
systems), CD45, CD31 and CD11b conjugated with Allophycocyanin (R&D 
systems). The cells were sorted in a cell sorter (BD FACS AriaII) to recover fractions 
which were positive for Integrin α-7 and GFP, and negative for Sca-1, CD45, CD31 
and CD11b, and were used for DNA or RNA purifications. Alternatively, the 
percentage of GFP-positive satellite-like cells was assayed by flow cytometry (BD 
LSRII), as assessed by the expression of Integrin α-7 and GFP and the lack of CD45, 
CD31, Sca-1 and CD11b markers. Also, the quality of the satellite cell preparation 
was assessed by immunostaining for Pax7 on the isolated satellite cells. 
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Histology and histochemistry 
Muscle tissues were embedded in tragacanth gum and frozen in liquid nitrogen-cooled 
isopentane. Cryostat sections, 8-µm thick, were prepared with a Leica cryostat 
1860UV (Leica, Richmond, IL), fixed with 4% paraformaldehyde, washed and 
permeabilized in PBS containing 1% BSA and 0.2% (w/v) Triton X-100, followed by 
one hour of blocking with 10% goat serum at room temperature. Immunofluorescence 
staining was performed by overnight incubation at 4°C with the following primary 
antibodies: Mouse anti-dystrophin DYS1 and DYS2 1:40 (Novocastra, Newcastle 
upon Tyne, UK), rabbit anti-laminin 1:100 (Sigma), chicken anti-GFP 1:1000 
(Abcam, Cambridge, UK), mouse anti-β-galactosidase 1:100 (Abnova), mouse anti-
myosin heavy chain 1:200 (eBioscience, Thermo Fisher Scientific, Lafayette, CO), α-
sarcoglycan 1:100 (Novocastra), β-sarcoglycan 1:100 (Novocastra), β-dystroglycan 
1:100 (Novocastra), n-nitric oxide synthase 1:100 (nNOS) (Invitrogen), syntrophin 
1:100 (Invitrogen). For anti-mouse Pax7 (R&D systems) immunostaining, samples 
were first stained with the required primary antibodies other than Pax7. Samples were 
then immersed in sodium citrate buffer (10 mM, pH = 6.0) at 100°C for demasking 
the antigen epitopes, and incubated overnight at 4°0C with anti-mouse Pax7. After 
incubation with primary antibodies, the samples were washed with 0.2% Triton X-100 
PBS and then incubated with the secondary goat antibodies 1:500 (Invitrogen) for one 
hour. After three washes, slides were mounted using fluorescent mounting medium 
containing 4',6-diamidino-2-phenylindole (DAPI) (Southern Biotech, Birmingham, 
AL) and observed under a fluorescence microscope (Leica-DM5500/Olympus 
Slidescanner VS120-L100).  
Cryostat sections were used for hematoxylin and eosin (Sigma) staining, X-gal 
staining (Invitrogen), Masson trichome staining (Sigma) using standard protocols. 
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The slides were then observed under microscopes and images were captured for 
further analysis (Leica DM5500 / Olympus SlideScanner VS120-L100).  
Image analysis was performed using ImageJ software (NIH, Bethesda, MD). For 
quantification of number of dystrophin positive fibers per muscle cross section, 
images of the whole cross section were generated using an Olympus SlideScanner 
(Olympus, Tokyo, Japan). Numbers of dystrophin positive fibers were counted using 
the cell counter plugin of ImageJ. For each muscle, fibers were counted at seven 
different distances (2 to 8 mm) from the distal tendon. Final calculations were made 
using the values obtained from 4 to 8 muscles per group. Cross-sectional area (CSA) 
was measured by tracing transversal myofibers with the freehand selection tool and 
fiber area measured with the measurement analysis tool. Random fields were chosen 
from images of the whole cross section made using a slide scanner (Olympus 
SlideScanner), and at least 150 myofibers per cross section were counted. Between 4 
to 8 muscles were analyzed per condition, and plots of the CSA distribution were 
made using GraphPad Prism (GraphPad, San Diego, CA). Presence of fibrotic, 
adipose, scar tissue and infiltrates was evaluated using the same images. This analysis 
was performed by separating the hematoxylin component and eosin component of the 
images and calculating the percentage of area occupied by the infiltrating material. 
This analysis gave an estimate of muscle damage in the treated muscles as compared 
to the controls.   
 
Tumorigenesis assay 
In order to exclude potential tumorigenic mutations due to transposon vector 
integration events, CD1 nude mice (n=8 per group) were injected subcutaneously in 
the dorsal flank, with 2,000,000 mdx (DYS GFP PB) MABs resuspended in 100µl of 
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calcium magnesium free PBS. As controls, one group of mice was injected with the 
same number of HeLa cells as positive control for tumor formation, another group 
was injected with untransfected mdx MABs, and a third group was mock injected with 
PBS. The mice were monitored for any detectable tumor masses for eight months 
after cell transplantations. The positive control, HeLa cells injected mice developed 
tumors within one month after injections, whereas the other test mice did not display 
any tumor. 
 
PCR and gene copy number assays 
DNA from MABs and mouse muscles was purified using the DNeasy Blood & Tissue 
Kit (Qiagen, Hilden, Germany) as per the manufacturer’s instructions. RNA was 
purified from MABs using NucleoSpin® RNA kit (Macherey Nagel, Düren, 
Germany) and from mouse muscles using RNeasy Fibrous Tissue Mini Kit (Qiagen). 
cDNA was prepared from 500 ng of each RNA sample using the GoScript™ Reverse 
Transcription System (Promega, Madison, WI). PCR on mouse muscle genomic 
DNA, MABs DNA and RT-PCR on mouse cDNA was carried out using Q5® High-
Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA) according to 
standard protocols. Endpoint PCR analysis was carried out to detect different regions 
on the human dystrophin coding sequence using primers enlisted as hDYS1, hDYS2 
and hDYS3 (Table S1a). The primers (Microsynth, Baglach, Switzerland) used for the 
different PCR, quantitative PCR (qPCR) with reverse transcription (RT-qPCR), for 
transgene copy number or relative RNA level assays, have been listed in Table S1. 
qPCR and RT-qPCR amplifications were carried out using the LightCycler® 480 
SYBR Green I Master mix (Roche, Basel, Switzerland), and the ABI/Prism 7900 HT 
Thermocycler. Each DNA or cDNA sample was amplified in triplicates, and cDNA 
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levels were normalized to that of the housekeeping gene encoding TATA-binding 
protein (TBP), by the comparative threshold cycle (Ct) method. Fold-changes were 
determined using the equation 2−∆∆Ct. Transposon copy number was quantified by 
methods of serial dilution,52 relative to a reference gene present as one copy per 
haploid genome (TBP), and by whole genome sequencing coverage. The primers used 
for this were on the dystrophin region (Supplementary Table S1). 
 
Genome sequencing and analysis 
High molecular weight DNA was isolated from mdx (DYS PB) MABs using Blood & 
Cell Culture DNA Mini Kit (Qiagen). Whole genome sequencing of mdx (DYS PB) 
MABs was carried out by the Genomic Technologies Facility of University of 
Lausanne using the single molecule, real-time (SMRT) sequencing technology 
(Pacific Biosciences, Menlo Park, CA). The data derived from 18 SMRT cells yielded 
a genome coverage of approximately 7.7-fold from high quality sequences, which was 
then used to detect dystrophin integration sites mediated by the transposase, as 
described previously.53 Integration events were retrieved, using a threshold of more 
than 10 kb regions of similarity to the transposon sequence, to identify reads spanning 
both extremities of transposon inserts. At least one of the two transposon borders 
could be characterized and found to contain the TTAA signature sequence indicative 
of PB transposition at the junction with the mouse genome, thus confirming that the 
integration events were transposase mediated.  
 
Western blot 
Frozen tissues were prepared and used for immunoblotting as described 
previously.54,55 Muscle extracts (3-30 µg/lane) were resolved by SDS-PAGE, and 
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proteins were transferred onto nitrocellulose membranes according to standard 
procedures. Membranes were blocked for 1 hour in TBST (20 mmol/L Tris-base, 150 
mmol/L NaCl, 0.1% Tween-20, pH 7.5) containing 5% nonfat dry milk and incubated 
overnight at 4°C with a primary antibody (mouse anti-dystrophin MANDYS8, 
ThermoFisher; Mouse anti-alpha-actinin, Sigma). After extensive washing, 
membranes were incubated for 1 hour with the appropriate horseradish peroxidase-
conjugated secondary antibody in TBST containing 5% milk. Detection was done by 
chemiluminescence (ECL plus kit; Amersham, Little Chalfont, UK) using Fusion 
Pulse. Densitometric analysis was performed with ImageJ software. Signals were 
normalized to the alpha-actinin content. 
 
Assessement of muscle function in situ 
At the end of the treatment period, the contractile properties of the TA were measured 
in situ essentially as described elsewhere.55,37,54 In brief, mice were deeply 
anesthetized, the knee joint was immobilized, the distal tendon of the TA was 
attached to a force transducer, intramuscular electrodes were inserted, and the tension 
developed by the TA in response to 0.5 ms-long electrical stimulations was recorded 
isometrically. The fatigability of the TA exposed to repetitive maximal tetanic 
contractions was determined: the TA were stimulated at 200 Hz for 200 ms, resulting 
in fused tetani. A total of 20 tetani were delivered at 30s intervals. The force 
generated at every tetanus was expressed as the percentage of the initial force. The 
extent of force loss was calculated from the force remaining at the end of the assay. 
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Atomic force microscopy assays 
The restoration of the resistance to elastic deformation of individual dystrophin-
expressing myofibers was assessed using atomic force microscopy as described 
previously.37 After mouse sacrifice, the TA muscles were dissected out and 
immediately frozen in liquid nitrogen-cooled isopentane and stored at -70C until 
thawing for use in AFM assays. Before performing measurements, a 1 mm-thick 
section of the muscle was cut and glued onto a glass coverslip using two 0.5 µl 
droplets of cyanoacrylate adhesive (AXIA) placed at both extremities of the muscle 
slice. The slice was immediately immersed in DMEM and AFM measurements were 
performed. 100-300 locations were assayed on each muscle slice. AFM assays were 
performed using a commercially available device (PSIA XE120, Park Systems, 
Korea) equipped with the “liquid cell” setup. Standard silicon nitride, gold-coated 
cantilevers (ORC8, Bruker), with a nominal spring constant value of 0.38 N/m were 
used in all measurements. To determine the mean value of the Young's modulus 
(calculated for the indentation depth of 200 nm), the modulus distribution was fitted 
with the Gaussian function. The center of the distribution corresponds to the mean 
value while half of its width, taken at half height, denotes the standard deviation.  
 
Statistical analysis 
Data were analyzed using GraphPad Prism 7 and Microsoft Excel. Results were 
represented as mean ± standard deviation (S.D.). Statistical analyses were performed 
using the Mann-Whitney tests for significance of differences. P values lower than 
0.05 were considered as significant. 
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SUPPLEMENTARY MATERIAL 
Figure S1. Characterization of mdx MABs. 
Figure S2. Transposition efficiency determination and quantification of 
transposon integration events in mdx MABs. 
Figure S3. Whole muscle mounts of transplanted muscles 
Figure S4. Dystrophin expression in intra-muscularly and intra-arterially 
transplanted mdx/SCID muscles.  
Figure S5. Slide scanner images of whole TA cross-sections. 
Figure S6. Confocal microscopy 3-D reconstruction of dystrophin 
expression in transplanted and control muscles. 
Figure S7. Dystrophin associated proteins in intra-muscularly transplanted 
mdx/SCID TA muscles. 
Figure S8. Endpoint PCR and RT-PCR analysis of transplanted muscles.  
Figure S9.  Fluorescence associated cell-sorting strategy for satellite cell 
isolation. 
Figure S10. Pax7 staining in isolated satellite cell-enriched populations. 
Figure S11. Masson trichome staining in intra-muscularly transplanted 
mdx/SCID TA muscles. 
 
Table S1. PCR primers used in the study 
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LEGENDS TO FIGURES 
 
Figure 1. Strategy used for genetic modification of mdx MABs and 
transplantation in mdx/SCID mice. (1) Isolation of mdx MABs from muscles of 
mdx mice. (2) Electroporation of transposon donor plasmids (harboring human 
dystrophin and/or the GFP or nlacZ reporter) and transposase plasmids shown in the 
top part of the figure panel.  (3) Selection of polyclonal MAB populations by culture 
in the presence of puromycin for three weeks. These modified and selected mdx 
MABs are called mdx (DYS PB) MABs, mdx (DYS GFP PB) MABs, or mdx (DYS 
nlacZ PB) MABs, depending on whether they were transfected with the dystrophin 
(DYS), green fluorescent protein (GFP), /-targeted beta-galactosidase (nlacZ), and/or 
transposase (PB) expression vectors. (4) After in vitro characterization, genetically 
modified and selected MABs were transplanted in mdx/SCID mice either intra-
muscularly or intra-arterially. (5) Analysis of dystrophin expression and of the 
morphological and functional amelioration of the transplanted muscles.  
 
Figure 2. Characterization of mdx MABs carrying dystrophin- and GFP-
expressing PiggyBac transposons. (A) Phase contrast (left hand side panel) and 
fluorescence microscopy (right hand side panel) analysis of mdx (DYS GFP PB) 
MABs transfected with PiggyBac transposon harboring dystrophin and GFP 
expression cassettes and selected for puromycin resistance. Scale bar, 100 µm. (B) In 
vitro differentiation of the mdx (DYS GFP PB) MABs by co-culture in differentiation 
medium with a GFP-negative mouse myoblast (C2C12) cell line. GFP fluorescence 
(green, left panel), with myosin heavy chain immunofluorescence of myotubes (red) 
and DAPI nuclear staining (blue, right panel), was performed after five days of 
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culture in differentiation medium showing a multinucleated GFP and MyHC positive 
myotube. Scale bar, 50 µm. (C) Flow cytometry analysis for the presence of MAB 
cell surface markers on untransfected mdx MABs or transfected mdx (DYS PB) 
MABs populations, as indicated (n=4). (D) Reverse transcriptase and quantitative 
real-time PCR (qPCR) analysis of relative transcript levels for different MAB markers 
in mdx MABs and mdx (DYS PB) MABs. Data are represented as the mean ± S.D. of 
three independent experiments, each performed in triplicates (E). In vitro 
transmigration of MABs performed on endothelial cells (H5V cell line) cultured on a 
gelatin-coated filter. GFP positive MABs were added on the upper surface of the 
filters and after 11h, the MABs that had migrated on the other side of the filter were 
quantified. The number of mdx (DYS GFP PB) MABs and mdx  (GFP PB) MABs 
normalized to the area is represented as the mean ± S.D. from three experiments, each 
performed in triplicates (P<0.05, negative control vs. test group). (F) Endpoint PCR 
analysis showing the presence of different loci (denoted as hDYS1, hDYS2, hDYS3) 
of the human dystrophin coding sequence in selected and cultured mdx (DYS PB) 
MABs. Lane 1: mdx (DYS PB) MABs; Lane 2: non-transfected mdx MABs; Lane 3: 
Dystrophin expression vector; Lane 4: Human MABs control; Lane 5: Water control. 
The results of three independent experiments are shown. 
 
Figure 3. Integration site profile of transposon in mdx (DYS PB) MABs (A) 
Distribution of integration sites over the different chromosomes to assess a possible 
transposition preference. (B) Graph showing the percentage of integrations in introns, 
exons, and in different parts of intergenic regions (<1kb upstream or downstream of 
coding sequences; >1kb upstream or downstream of coding sequences), n = 44. (C) 
Mapping of intergenic integration events based on their distance from the closest 
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gene. Upstream or downstream transposition events are indicated by negative or 
positive numbers, respectively. Each bar denotes an individual intergenic integration 
event.  
 
Figure 4. Dystrophin expression following intra-muscular transplants. Muscles 
were analyzed either after 45 days (short term, ST) or 120 days (long term, LT) after a 
single transplant, or 45 days after the last of three transplants performed at intervals of 
three weeks. (A) Cross sections of mdx/SCID mouse TA muscles are shown for a 
mock transplanted muscle (top panels), or for a muscle transplanted three times with 
mdx (DYS GFP PB) MABs (middle panels). The bottom panels show the TA cross-
section of a non-dystrophic B6/SCID mouse. Muscles were immunostained for 
dystrophin only (left panels), and additionally for laminin and DAPI (right panels), as 
indicated. Scale bar, 50 µm. (B) Box-and-whisker plots of the number of dystrophin 
positive fibers per TA muscle cross section, generated at the indicated distances in 
mm from the distal tendon, short term or long term after a single transplant or after 
three transplants, as indicated. Box-and-whisker plots represent the 50th percentile as 
the middle line in the box, the 25th and 75th percentile as the top and bottom of the box 
respectively, and the smallest and largest values as the top and bottom of the 
whiskers. (C) DNA levels of human dystrophin, plasmid backbone, transposase as 
assessed by qPCR analysis performed on transplanted muscles or in vitro selected 
mdx (DYS GFP PB) MABs. All the qPCR values were normalized to those of short-
term single transplant muscles, which were set to one. Data are represented as mean ± 
S.D. from more than six muscles per condition, * P≤0.05; ** P≤0.01 (D) Box plot of 
the overall numbers of dystrophin positive fibers from measurements performed at all 
distances from the distal tendon following the different transplant conditions, *** 
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P≤0.001 (n≥6). (E) Transcript levels of human dystrophin as assessed by qPCR 
analysis performed on transplanted muscles or in vitro selected mdx (DYS GFP PB) 
MABs. All the qPCR values were normalized to those of short-term single transplant 
muscles, which were set to one. Data are represented as mean ± S.D from more than 
six muscles per condition, * P≤0.05; ** P≤0.01; n.d.: not detectable (n≥6). (F) 
Western blot showing dystrophin expression in the mdx/SCID muscles transplanted 
one time with mdx (DYS PB) MABs, short term (1 trans) or transplanted three times 
with mdx (DYS PB) MABs, six weeks after the last transplant (3 trans) vs non 
transplanted mdx muscles (0 trans) or non-transplanted B6 muscles, using α-actinin 
expression as control. Lanes 1 to 3:  wild type B6/SCID control (30 µg; 9 µg and 3 µg 
protein loaded, respectively); Lane 4, 5: mdx/SCID mock injected (30 µg); Lanes 6, 7: 
mdx/SCID three transplants (mdx (DYS PB) MABs) TA muscles (30 µg); Lane 8, 9:  
mdx/SCID one transplant (mdx (DYS PB) MABs) TA muscles (30 µg). The graph 
shows the corresponding densitometry analysis of the western blot where values are 
expressed relative to the total dystrophin levels of wild type muscles, which were set 
to 100%. 
 
Figure 5. Reconstitution of the satellite cell niche by donor MABs in intra-
muscularly transplanted muscles 
Immunofluorescence staining images showing Pax7 staining for satellite cells, and β-
galactosidase staining for transplanted mdx (DYS nLacZ PB) MABs. Top panels 
show the co-localization of a Pax7 and β-galactosidase staining of positive nucleus 
under the basal lamina (MAB-derived satellite cell). Bottom panel shows a Pax7 
positive nucleus that is not β-galactosidase positive under the basal lamina (resident 
satellite cell). Scale bar, 20 µm. (B) Fluorescence-based cell sorting of GFP positive 
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satellite cells (mdx DYS GFP PB MAB-derived) and GFP negative (resident) satellite 
cells. Boxes in all left panels highlight the proportion of Sca-1- and Integrin-α7+ cells 
among the subpopulation of CD31-, CD45-, CD11b- mononuclear cells, among which 
the GFP+ cells are boxed on right hand side panels, i.e. there are 3.17% of GFP+ cells 
among the Sca-1-, Integrin-α7+, CD31-, CD45-, CD11b- mononuclear cells isolated 
from the mdx SCID mice muscles after 3 transplantations. (C) Averages of the 
percentage of GFP+ satellite cells derived from transplanted mdx (DYS GFP PB) 
MABs from the total population of satellite cells in mdx/SCID three transplants mice, 
isolated six weeks after last transplant, and mdx/SCID single transplant 24 weeks after 
transplantation. Values are expressed as mean ± S.D of values from different muscles 
used for satellite cell isolation (n = 4 for each condition). (D) qPCR analysis of 
transcript levels of the Pax7 and integrin-α7 satellite cell markers in the resident 
satellite cell population and donor MAB-derived satellite cells of transplanted 
muscles; n.d., not detectable)  
 
Figure 6. Morphological amelioration of the dystrophic phenotype after intra-
muscular transplantation of genetically modified MABs. (A) Hematoxlyin and 
eosin stained images of TA muscle cross sections of a wild type B6/SCID mouse, 
mdx/SCID single transplant six weeks after transplantation (ST), mdx/SCID single 
transplant 24 weeks after transplantation (LT), mdx/SCID three transplants six weeks 
after last transplant, and mdx/SCID 0 transplant (mock injected) muscle. Scale bar, 
100 µm. (B) Box-and-whisker plot showing the distribution of the area of individual 
myofibers, as determined from cross sections of TA muscles from wild type B6/SCID 
mice, mdx/SCID single transplant mice six weeks after transplantation (1 trans ST), 
mdx/SCID single transplant mice 24 weeks after transplantation (1 trans LT), 
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mdx/SCID three transplants mice six weeks after last transplant (3 trans), and 
mdx/SCID mock injected mice (0 trans) (n≥6). (C) Box-and-whisker plot showing 
percentage of non-muscle cells (fibrotic and adipose tissue, infiltrating cells) in the 
different mouse groups. ** P≤0.01; *** P≤0.001 (n≥6). 
 
Figure 7. Functional amelioration of the dystrophic phenotype after intra-
muscular transplantation of genetically modified mesoangioblasts.  
 
(A) AFM-based distributions of Young’s modulus (E) obtained for muscles explanted 
from wild type B6 SCID mice, mdx SCID single transplant short-term mice six weeks 
after transplantation, mdx SCID three transplants mice six weeks after last transplant, 
and mdx SCID mock injected mice. The Y-axis represents the number of locations 
assayed and the X-axis denotes Young’s modulus value grouped in 2 kPa bins. 
Gaussian function was fitted to determine the indicated average Young’ modulus 
value of each group. n = 8 to 10 muscles per group. (B) Improved muscle function 
measured in situ in living mice. In the TA of wild type B6/SCID mice, mdx/SCID 
three transplants mice six weeks after last transplant, and mdx/SCID mock injected 
mice, progressive loss of force was recorded as tetanic stimuli were delivered. This 
illustrates that mock-injected mdx/SCID mice lost force much faster than their wild 
type counterparts, and that the mdx/SCID mice transplanted 3 times had a much lower 
rate of force loss. (C) Improved muscle function measured in situ in living mice. 
Quantification of force loss. Force drop measured at the end of the assay, was 
expressed as percentage of initial force.  The force drop in mock-injected mdx/SCID 
mice was 3-fold higher than in the mock-injected B6/SCID mice. The force drop was 
significantly prevented in mdx/SCID mice transplanted 3 times (recovery index 
61.6%). n = 9 to 12 muscles per group. * P≤0.05; ** P≤0.01; *** P≤0.001. 
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This study reports full-length dystrophin expression from PiggyBac transposon vectors 
transfected in murine mesoangioblast progenitor cells (MAB), as a 
potential therapeutic autologous cell transplantation approach. Intramuscular MAB 
transplantation into dmd mice yielded stable dystrophin expression, restored a normal 
resistance for 80% of the myofibers and increased muscle resistance to fatigue.  
  
